The latest news from academia, regulators
research labs and other things of interest
Posted: Aug 01, 2016
Lab-on-a-Chip breakthrough aims to help physicians detect cancer and diseases at the nanoscale
(Nanowerk News) IBM scientists have developed a new lab-on-a-chip technology that can, for the first time, separate biological particles at the nanoscale and could help enable physicians to detect diseases such as cancer before symptoms appear.
As reported today in the journal Nature Nanotechnology ("Nanoscale Lateral Displacement Arrays for Separation of Exosomes and Colloids Down to 20nm"), the IBM team's results show size-based separation of bioparticles down to 20 nanometers (nm) in diameter, a scale that gives access to important particles such as DNA, viruses and exosomes. Once separated, these particles can be analyzed by physicians to potentially reveal signs of disease even before patients experience any physical symptoms and when the outcome from treatment is most positive. Until now, the smallest bioparticle that could be separated by size with on-chip technologies was about 50 times or larger, for example, separation of circulating tumor cells from other biological components.
Artistic rendering of IBM's nanoDLD technology. (Image: Ella Maru Studio for IBM Research)
IBM is collaborating with a team from the Icahn School of Medicine at Mount Sinai to continue development of this lab-on-a-chip technology and plans to test it on prostate cancer, the most common cancer in men in the U.S.
In the era of precision medicine, exosomes are increasingly being viewed as useful biomarkers for the diagnosis and prognosis of malignant tumors. Exosomes are released in easily accessible bodily fluids such as saliva, urine or blood. They represent a precious biomedical tool as they can be used in the context of less invasive liquid biopsies to reveal the origin and nature of a cancer.
The IBM team targeted exosomes with their lab-on-chip technology as existing scientific techniques face challenges for separating and purifying exosomes in liquid biopsies. Exosomes range in size from 20-140nm and contain information about the health of the originating cell that they are shed from. A determination of the size, surface proteins and nucleic acid cargo carried by exosomes can give essential information about the presence and state of developing cancer and other diseases.
IBM's results show they could separate and detect particles as small as 20 nm from smaller particles, that exosomes of size 100 nm and larger could be separated from smaller exosomes, and that separation can take place in spite of diffusion, a hallmark of particle dynamics at these small scales. With Mount Sinai, IBM plans to confirm their technology is able to pick up exosomes with cancer-specific biomarkers from patient liquid biopsies.
Extremely scaled nanoDLD gap. (Image: IBM Research)
"The ability to sort and enrich biomarkers at the nanoscale in chip-based technologies opens the door to understanding diseases such as cancer as well as viruses like the flu or Zika," said Gustavo Stolovitzky, Program Director of Translational Systems Biology and Nanobiotechnology at IBM Research. "This extra amount of time could allow physicians to make more informed decisions and when the prognosis for treatment options is most positive."
With the ability to sort bioparticles at the nanoscale, Mount Sinai hopes that IBM's technology can provide a new method to eavesdrop on the messages carried by exosomes for cell-to-cell communications. This can elucidate important questions about the biology of diseases as well as pave the way to noninvasive and eventually affordable point-of-care diagnostic tools. Monitoring this intercellular conversation more regularly could allow medical experts to track an individual's state of health or progression of a disease.
"When we are ahead of the disease we usually can address it well; but if the disease is ahead of us, the journey is usually much more difficult. One of the important developments that we are attempting in this collaboration is to have the basic grounds to identify exosome signatures that can be there very early on before symptoms appear or before a disease becomes worse," said Carlos Cordon-Cardo, MD, PhD, Chair of the Department of Pathology at the Mount Sinai Health System and Professor of Pathology, Genetics and Genomic Sciences, and Oncological Sciences at the Icahn School of Medicine. "By bringing together Mount Sinai's domain expertise in cancer and pathology with IBM's systems biology experience and its latest nanoscale separation technology, the hope is to look for specific, sensitive biomarkers in exosomes that represent a new frontier to offering clues that might hold the answer to whether a person has cancer or how to treat it."
A view of IBM Research's nanoDLD chip mounted in a microfluidic jig. The technology allows a liquid sample to be passed, in continuous flow, through a silicon chip containing an asymmetric pillar array. This array allows the system to sort a microscopic waterfall of nanoparticles, separating particles by size down to tens of nanometers resolution. IBM has already scaled down the chip size to 2cm by 2cm, while continuing development to increase the device density to improve functionality and throughput. (Image: IBM Research)
Sorting bioparticles at the nanoscale
Lab-on-a-chip technologies have become an incredibly helpful tool for physicians as they can be significantly faster, portable, easy to use and require less sample volume to help detect diseases. The goal is to shrink down to a single silicon chip all of the processes necessary to analyze a disease that would normally be carried out in a full-scale biochemistry lab.
Using a technology called nanoscale deterministic lateral displacement, or nano-DLD, IBM Scientists Joshua Smith and Benjamin Wunsch led development of a lab-on-a-chip technology that allows a liquid sample to be passed, in continuous flow, through a silicon chip containing an asymmetric pillar array. This array allows the system to sort a microscopic waterfall of nanoparticles, separating particles by size down to tens of nanometers resolution. IBM has already scaled down the chip size to 2cm by 2cm, while continuing development to increase the technology density to improve functionality and throughput.
Much like how a road through a small tunnel only allows smaller cars to pass while forcing bigger trucks to detour around, nano-DLD uses a set of pillars to deflect larger particles while allowing smaller particles to flow through the gaps of the pillar array unabated, effectively separating this particle "traffic" by size while not disrupting flow. Interestingly, IBM scientists noticed that nano-DLD arrays can also split a mixture of many different particle sizes into a spread of streams, much like a prism splits white light into different colors. The continuous flow nature of this technology circumvents stop-and-go batch processing typical of conventional separation techniques.
Leveraging IBM's vast semiconductor expertise with its growing capabilities in experimental biology, IBM scientists used manufacturable silicon processes to produce the nano-DLD arrays for their lab-on-a-chip technology. As part of its on-going strategy, the IBM team is working to increase the diversity of bioparticles that can be separated with their technology, and improving the precision and specificity for real-world clinical applications.